Outset Medical, Inc. Common Stock (OM) Stock Price
OMStock
$3.94−70.44%52W
Market Cap$74.06M
P/E—
PEG Ratio—
Div yield—
Beta1.99
OM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-19.33%
Price vs S&P 500 (4W)27.61%
VGM Score56.82
OM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.72 | -$0.80 | -11.63%(-$0.08) | |
| Q1 2026 | -$0.79 | -$0.83 | -5.06%(-$0.04) | |
| Q4 2025 | -$0.68 | -$0.84 | -24.44%(-$0.16) | |
| Q3 2025 | -$0.66 | -$0.69 | -5.34%(-$0.03) | |
| Q2 2025 | -$0.98 | -$0.84 | +14.50%(+$0.14) |
OM Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.08
4.18
4.18
4.18
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
OMOutset Medical, Inc. Common Stock | A | C | C | 0.6x | 19.1% | 41.8% | -56.1% | $3.94 |
| MDTMedtronic plc | B | C | B | 3.2x | 3.8% | 65.7% | 18.1% | $94.75 |
| ITGRInteger Holdings Corporation | C | C | A | 2.3x | 11.6% | 26.1% | 9.7% | $126.70 |
| LIVNLivaNova PLC Ordinary Shares | C | B | B | 2.9x | 8.2% | 68.1% | 12.5% | $77.58 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | 3.7x | 88.2% | 58.7% | 12.2% | $70.78 |
| AXGNAxogen, Inc. Common Stock | F | B | B | 8.1x | 14.9% | 74.6% | -11.8% | $34.62 |
| BLFSBioLife Solutions Inc. | F | C | A | 18.4x | 14.9% | 63.9% | 2.9% | $38.61 |
| CNMDCONMED Corporation | B | C | B | 1.0x | 9.8% | 55.8% | 8.0% | $46.72 |
| CBLLCeriBell, Inc. Common Stock | F | A | A | 9.4x | — | 88.9% | -68.6% | $25.04 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | 2.2x | 12.4% | 76.5% | 18.5% | $14.16 |
| CVCapsoVision, Inc. Common Stock | F | D | B | 25.0x | — | 50.9% | -217.1% | $6.53 |
About Outset Medical, Inc. Common Stock
Outset Medical Inc manufactures the Tablo dialysis console, designed to reduce the cost and complexity of dialysis treatment. The company generates revenue from both capital equipment sales and recurring consumables, including cartridges and accessories. This dual revenue model captures both upfront and ongoing customer spend in the nephrology care market.